Drug treatments for adjuvant chemotherapy in breast cancer: Recent trials and future directions

Expert Review of Anticancer Therapy

Volumn 6, Issue 3, 2006, Pages 427-436

  Dang, Chau T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Treatment

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TAXOID;

ANEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG TARGETING; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; PACLITAXEL; TAXOIDS;

EID: 33644908479     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.3.427     Document Type: Review

References (31)

1. Fisher B, Foster R, Gardner B et al. Relation of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52, 1551-1557 (1983).
2. Fornier M, Munster P, Seidman A. Update on the management of advanced breast cancer. Oncology 13, 647-658 (1999).
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. (EBCTCG). Lancet 365, 1687-1717 (2005).
4. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1, 2000. J. Natl Cancer Inst. Monogr. 93, 979-989 (2001).
5. Goldhirsch A, Glick, JH, Gelber RD et al. Meeting highlights: international consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16, 1569-1583 (2005).
6. Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line therapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J. Clin. Oncol. 21, 968-975 (2003).
7. Jassem J, Pienkowski T, Pluzanska A et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized Phase III multicenter trial. J. Clin. Oncol. 19, 1707-1715 (2001).
8. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976-983 (2003).
9. Mamounas EP, Bryant J, Lembersky BC et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. J. Clin. Oncol. 23, 3686-3696 (2005).
10. Buzdar AU, Singletary SE, Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin. Cancer Res. 8, 1073-1079 (2002).
11. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003).
12. Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 143).
13. Hudis C, Citron M, Berry D et al. Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res. Treat. 89 (2005) (Abstract 49).
14. Citron ML, Berry DA, Cirrincione C et al. Dose-dense (DD) AC followed by paclitaxel is associated with more frequent moderate anemia compared to sequential (s) and/or less DD treatment: update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, and NCCTG. Proc. Am. Soc. Clin. Oncol. 24, 33S (2005) (Abstract 620).
15. Berry DA, Cirrincione C, Henderson IC et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res. Treat. 88(Suppl. 1), S17 (2004) (Abstract 29).
16. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302-2313 (2005).
17. Goldstein LJ, O'Neill A, Sparano JA et al. E2197: Phase III of AT vs AC in the adjuvant treatment of node-positive and high-risk node-negative breast cancer. Proc. Am. Soc. Clin. Oncol. 24 (2005) (Abstract 512).
18. Roche H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res. Treat. 88 (2004) (Abstract 27).
19. Bear HD, Anderson S, Smith RE et al. A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. 88, S16 (2004) (Abstract 26).
20. Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin. Breast Cancer 3(Suppl. 2), S69-S74 (2002).
21. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monogr. 30, 96-102 (2001).
22. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once very 3 weeks. J. Clin. Oncol. 23, 5983-5992 (2005).
23. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase II study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc. Am. Soc. Clin. Oncol. 23, 6S (2004) (Abstract 512).
24. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
25. Perez EA, Suman VJ, Davidson N et al. NCCTG 9831: May 2005 update. Proc. Am. Soc. Clin. Oncol. (2005) (Oral presentation).
26. Slamon D, Eiermann W, Robert N et al. Phase III trial comparing AC-T with AC-TH with TCH in the adjuvant treatment of HER2 positive breast cancer patients: first interim efficacy analysis. Breast Cancer Res. Treat. 89 (2005) (Abstract 1).
27. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
28. Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: rationale for MA.21 study. Oncology 15, 7-13 (2001).
29. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005).
30. Dang C, Smith K, Lake D et al. Preliminary cardiac safety result of dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer. Breast Cancer Res. Treat. 89 (2005) (Abstract 2041).
31. Miller K, Wang M, Gralaw J et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res. Treat. 89 (2005) (Abstract 3).